Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · IEX Real-Time Price · USD
4.400
-0.010 (-0.23%)
At close: Apr 26, 2024, 3:58 PM
4.530
+0.130 (2.95%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Company Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development.
The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease.
It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix, Inc.
Country | United States |
Founded | 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Dr. Alan J. Tuchman M.D., MBA(FAAN) |
Contact Details
Address: 1185 Avenue Of The Americas, 3rd Floor New York, New York 10036 United States | |
Phone | (973) 242-0005 |
Website | synaptogen.com |
Stock Details
Ticker Symbol | SNPX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001571934 |
CUSIP Number | 87167T201 |
ISIN Number | US87167T2015 |
Employer ID | 46-1585656 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Alan J. Tuchman M.D., MBA(FAAN) | Chief Executive Officer and Director |
Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer and Director |
Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer and Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 4, 2024 | 8-K | Current Report |
Apr 1, 2024 | 10-K | Annual Report |
Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 21, 2023 | 8-K | Current Report |
Nov 14, 2023 | ARS | Filing |
Nov 14, 2023 | 10-Q | Quarterly Report |
Nov 13, 2023 | DEF 14A | Other definitive proxy statements |
Nov 6, 2023 | 8-K | Current Report |
Nov 3, 2023 | PRE 14A | Other preliminary proxy statements |
Sep 22, 2023 | 8-K | Current Report |